Can drug price hikes via debranding be prevented?

Farasat Bokhari, Bruce Lyons

Research output: Contribution to journalArticle

44 Downloads (Pure)

Abstract

Steep price hikes following the debranding of off-patent medicines are becoming increasingly common in the UK, adding hundreds of millions to the NHS drugs bill. But can anything be done to prevent this?
Original languageEnglish
Pages (from-to)44-46
Number of pages3
JournalPrescriber
Volume28
Issue number4
DOIs
Publication statusPublished - 30 Apr 2017

Cite this